Shopping Cart
Remove All
Your shopping cart is currently empty
Patritumab deruxtecan
(Synonyms: U3-1287, U31287, MK-1022, HER3-DXd, HER3DXd) Copy Product Info
🥰Excellent
Synonyms: U3-1287, U31287, MK-1022, HER3-DXd, HER3DXd
Catalog No. T77910 Copy Product Info
Purity: 95%
🥰Excellent
Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).
Patritumab deruxtecan
Cas No. 2227102-46-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $795 | In Stock | In Stock | |
| 5 mg | $2,320 | In Stock | In Stock | |
| 10 mg | $3,130 | - | In Stock | |
| 25 mg | $4,650 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC). |
| In vitro | Patritumab deruxtecan is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody (patritumab) directed against HER3 covalently linked to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Upon binding to HER3, HER3-DXd translocates to lysosomes, where the linker is cleaved by lysosomal enzymes that are upregulated in tumor cells. The cytotoxic payload is then free to enter the nucleus, leading to cell death and, because the payload is membrane permeable, has potential bystander antitumor effects. [1] |
| Synonyms | U3-1287, U31287, MK-1022, HER3-DXd, HER3DXd |
| Reactivity | Human |
| Verified Activity | Immobilized Human HER3/ERBB3 Protein (His) (TMPY-01389) at 1 μg/mL (100 μL/well) can bind Patritumab deruxtecan. The EC50 is 1.030 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | DXd |
| Gene ID | |
| Uniprot ID | |
| Target | ERBB3/HER3 |
| Molecular Weight | 155.2 kDa |
| Cas No. | 2227102-46-5 |
| Isotype | IgG1-DXd |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: Patritumab deruxtecan in vitro | Patritumab deruxtecan molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.